Diagnosing cystic fibrosis in newborn screening in Poland - 15 years of experience
- PMID: 26003066
Diagnosing cystic fibrosis in newborn screening in Poland - 15 years of experience
Abstract
Early diagnosis of cystic fibrosis (CF) made by the introduction of CF NBS (Cystic Fibrosis Newborn Screening) provides the opportunity to undertake preventive measures and provide treatment before the development of irreversible changes in the respiratory tract and other complications. CF NBS was conducted as a pilot programme in four Polish districts in the period 1999-2003. In 2006 CF NBS started again and was gradually extended across the country. The aim of this study was to show the evolution of the Polish CF NBS strategies and assess the diagnostic consequences of this programme.
Material and methods: The study involved children diagnosed and treated only in the IMiD Centre. The strategy in Polish CF NBS was modified over time. Firstly, the model IRT/IRT and IRT/IRT/DNA with one mutation was implemented, which was followed by IRT/DNA with a gradually expanding number of CFTR mutations (tab. I). Newborns with positive results of CF NBS were called to the CF IMiD Centre, and sweat tests were performed. The children diagnosed and children with mutations in both alleles of the CFTR gene even if at least one of them had undefined pathogenicity) were taken under IMiD Centre care. Sensitivity, specificity and positive predictive values during subsequent stages of CF NBS were calculated (tab. III).
Results: During the 1999-2003 pilot study 444 063 newborns underwent CF NBS and in 74 cases CF was diagnosed. 582 693 newborns were screened from September 2006 to December 2011 in four regions and 100 children were diagnosed with CF. The frequencies of CF in the Polish population in both screening periods were 1:5767 and 1:5712 respectively. Firstly, the IRT/IRT model was implemented, but the number of newborns called to the CF Centre was high - the PPV was 7.6%. In the next step CF NBS DNA analysis was used. Here sensitivity and specificity were high - nearly 100%. In the following years the number of mutations detected was expanded (including 16 most common ones in the Polish population). Due to the panel changes, the number of calls declined and the PPV (predictive positive value) improved (to 26.1%) after the application of expanded genetic analysis. Expanding the panel of mutations resulted in an increased number of carriers and observational subjects.
Conclusions: IRT/DNA strategy with expanded DNA analysis provides the opportunity for earlier CF diagnosis even in children with normal sweat test values. However, this model caused frequent carrier detection and inconclusive diagnosis in comparison to IRT/IRT or IRT/IRT/DNA with a limited number of mutations. Further research and changes in Polish CF NBS are needed to increase the PPV, while preserving high sensitivity and specificity..
Similar articles
-
A survey of newborn screening for cystic fibrosis in Europe.J Cyst Fibros. 2007 Jan;6(1):57-65. doi: 10.1016/j.jcf.2006.05.008. Epub 2006 Jul 25. J Cyst Fibros. 2007. PMID: 16870510
-
Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.Pediatrics. 2004 Jun;113(6):1573-81. doi: 10.1542/peds.113.6.1573. Pediatrics. 2004. PMID: 15173476
-
Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.J Cyst Fibros. 2014 May;13(3):267-74. doi: 10.1016/j.jcf.2013.10.012. Epub 2013 Nov 12. J Cyst Fibros. 2014. PMID: 24238947
-
Emerging issues in cystic fibrosis newborn screening.Curr Opin Pulm Med. 2010 Nov;16(6):584-90. doi: 10.1097/MCP.0b013e32833e9e27. Curr Opin Pulm Med. 2010. PMID: 20814308 Review.
-
Severe lung disease in children with cystic fibrosis missed in newborn screening.Pediatr Pulmonol. 2024 Jan;59(1):163-168. doi: 10.1002/ppul.26734. Epub 2023 Oct 27. Pediatr Pulmonol. 2024. PMID: 37888495 Review.
Cited by
-
Screening for cystic fibrosis in New York State: considerations for algorithm improvements.Eur J Pediatr. 2016 Feb;175(2):181-93. doi: 10.1007/s00431-015-2616-3. Epub 2015 Aug 21. Eur J Pediatr. 2016. PMID: 26293390
-
Clinical complications in children with false-negative results in cystic fibrosis newborn screening.J Pediatr (Rio J). 2022 Jul-Aug;98(4):419-424. doi: 10.1016/j.jped.2021.11.007. Epub 2021 Dec 22. J Pediatr (Rio J). 2022. PMID: 34953776 Free PMC article.
-
Impact of newborn screening for cystic fibrosis on clinical outcomes of pediatric patients: 10 years' experience in Lodz Voivodship.Ital J Pediatr. 2021 Apr 9;47(1):87. doi: 10.1186/s13052-021-01040-5. Ital J Pediatr. 2021. PMID: 33836782 Free PMC article.
-
Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process.J Med Screen. 2018 Mar;25(1):6-12. doi: 10.1177/0969141317692611. Epub 2017 Apr 28. J Med Screen. 2018. PMID: 28454512 Free PMC article.
-
The Role of Extended CFTR Gene Sequencing in Newborn Screening for Cystic Fibrosis.Int J Neonatal Screen. 2020 Mar 21;6(1):23. doi: 10.3390/ijns6010023. eCollection 2020 Mar. Int J Neonatal Screen. 2020. PMID: 33073020 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous